Page 7 - Repligen Corp News Today

Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair lifted their Q1 2023 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, April 12th. William Blair analyst M. Larew now expects that the biotechnology company will earn $0.72 per share for the quarter, up from their […]

Repligen Co. (NASDAQ:RGEN – Get Rating) shares traded up 4.3% during mid-day trading on Wednesday . The stock traded as high as $178.26 and last traded at $177.66. 322,077 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 547,335 shares. The stock had previously closed at $170.39. Analysts […]

Repligen (NASDAQ:RGEN – Get Rating) and Molecular Partners (NASDAQ:MOLN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Institutional and Insider Ownership 91.0% of Repligen shares are held by […]

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the […]

Repligen Co. (NASDAQ:RGEN – Get Rating) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average […]

Comerica Bank boosted its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 11.7% in the fourth quarter, HoldingsChannel reports. The firm owned 117,682 shares of the biotechnology company’s stock after buying an additional 12,309 shares during the period. Comerica Bank’s holdings in Repligen were worth $21,850,000 as of its most recent SEC filing. A […]

Inspire Investing LLC lifted its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 19.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,163 shares of the biotechnology company’s stock after purchasing an additional 1,320 shares during […]

Benchmark began coverage on shares of Repligen (NASDAQ:RGEN – Get Rating) in a report issued on Monday morning, The Fly reports. The firm issued a buy rating and a $230.00 price objective on the biotechnology company’s stock. RGEN has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of […]

Repligen Co. (NASDAQ:RGEN – Get Rating)’s stock price shot up 4.5% during mid-day trading on Monday . The company traded as high as $167.87 and last traded at $167.40. 133,416 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 571,400 shares. The stock had previously closed at $160.25. […]

Bank of New York Mellon Corp cut its stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 2.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 983,641 shares of the biotechnology company’s stock after selling 23,204 shares during the quarter. Bank of New York Mellon Corp’s holdings in Repligen were worth $184,049,000 […]